Ono takes further stride into oncology with Onyx deal
This article was originally published in Scrip
Executive Summary
Ono Pharmaceutical has signed its second oncology in-licensing deal in a week, this time with Onyx Pharmaceuticals for Japanese rights to two proteasome inhibitors.